Global study to spur new liver cirrhosis medicines
The FINANCIAL -- The ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study will follow 200 patients with cirrhosis – scarring caused by long-term damage of the liver – to uncover why some patients experience liver failure or develop liver cancer. Researchers from the Universities of Edinburgh and Newcastle hope their findings will lead to earlierThe FINANCIAL -- The ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study will follow 200 patients with cirrhosis – scarring caused by long-term damage of the liver – to uncover why some patients exp...
Source: finchannel.com